 |
 |
|
Home |
Current Issue |
Past Issues |
In the Clinic |
ACP Journal Club |
CME |
Collections |
Audio/Video |
Mobile |
Subscribe |
Tools |
Help |
ACP Online
|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 January 1994 | Volume 120 Issue 1 | Pages 8-11
Objective: To measure changes in spinal and femoral neck bone mineral densities in patients treated for Graves thyrotoxicosis.
Design: Cohort study.
Setting: Tertiary care center.
Patients: Fifteen women with active Graves thyrotoxicosis. Six patients were premenopausal and nine were postmenopausal. All patients had evidence of thyrotoxicosis as indicated by a raised total serum thyroxine, suppressed serum thyroid-stimulating hormone, and an elevated technetium-99m pertechnetate thyroid scan. A control group of 15 healthy volunteers matched for age, sex, and menopausal status were followed during the same period.
Measurements: Bone mineral density was measured by dual-energy x-ray absorptiometry at baseline and after 12 months of antithyroid therapy when euthyroidism had been achieved.
Results: After 12 months of therapy, total serum thyroxine, total serum triiodothyronine, serum alkaline phosphatase, and serum bone Gla-protein activities had returned to normal in all patients (P < 0.001 for all comparison between initial and final biochemical measurements). During this interval, the mean lumbar spine bone mineral increased from an initial value of 1.01 g/cm2 to 1.07 g/cm2, an increase of 6.6% per year (95% CI, 3.6% to 9.6%) (P < 0.001 compared with controls). Increases in femoral neck (1.2%/y; CI, –2.1% to 4.5%; P = 0.2 compared with controls) and femoral trochanter bone mineral (3.2%/y; CI, 2.4% to 8.7%; P = 0.2 compared with controls) were not statistically significant. Using forced-entry multiple regression analysis, the severity of the thyrotoxicosis was independently associated with the percentage increment in lumbar spine bone mineral density after 12 months of antithyroid therapy.
Conclusion: Effective treatment of Graves thyrotoxicosis was associated with increases in lumbar spine and femoral neck bone mineral. Although the changes in bone mineral were modest, our data suggest that thyrotoxic bone loss may be a reversible disorder.
Author and Article Information
From St George Hospital, Sydney, New South Wales, Australia.
ARTICLE
Thyrotoxic Bone Disease in Women: A Potentially Reversible Disorder
Requests for Reprints: Terrence Diamond, MB, Department of Endocrinology, St George Hospital, Kogarah, New South Wales, 2217, Australia.
Related articles in Annals:
This article has been cited by other articles:
|
|
 |
|
  E. ABE, L. SUN, J. MECHANICK, J. IQBAL, K. YAMOAH, R. BALIRAM, A. ARABI, B. S. MOONGA, T. F. DAVIES, and M. ZAIDI Bone Loss in Thyroid Disease: Role of Low TSH and High Thyroid Hormone Ann. N.Y. Acad. Sci., November 1, 2007; 1116(1): 383 - 391. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A C. Heijckmann, M. S P Huijberts, P. Geusens, J. de Vries, P. P C A Menheere, and B. H R Wolffenbuttel Hip bone mineral density, bone turnover and risk of fracture in patients on long-term suppressive L-thyroxine therapy for differentiated thyroid carcinoma Eur. J. Endocrinol., July 1, 2005; 153(1): 23 - 29. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Grieff The Hungry Bone Syndrome after Medical Treatment of Thyrotoxicosis Ann Intern Med, October 21, 2003; 139(8): 706 - 707. [Full Text] [PDF]
|
|
|
|
 |
|
 An interesting case of thirst and polyuria Postgrad. Med. J., April 1, 2002; 78(918): 251 - 251. [Full Text] [PDF]
|
|
|
|
 |
|
 M. C. Sheppard, R. Holder, and J. A. Franklyn Levothyroxine Treatment and Occurrence of Fracture of the Hip Arch Intern Med, February 11, 2002; 162(3): 338 - 343. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Pfeilschifter and I. J. Diel Osteoporosis Due to Cancer Treatment: Pathogenesis and Management J. Clin. Oncol., April 7, 2000; 18(7): 1570 - 1593. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Pantazi and P. D. Papapetrou Changes in Parameters of Bone and Mineral Metabolism during Therapy for Hyperthyroidism J. Clin. Endocrinol. Metab., March 1, 2000; 85(3): 1099 - 1106. [Abstract] [Full Text]
|
|
|
|
|
|
J. S. Adams, V. Kantorovich, C. Wu, M. Javanbakht, and B. W. Hollis Resolution of Vitamin D Insufficiency in Osteopenic Patients Results in Rapid Recovery of Bone Mineral Density J. Clin. Endocrinol. Metab., August 1, 1999; 84(8): 2729 - 2730. [Abstract] [Full Text]
|
|
|
|
 |
|
 Quality Standards Subcommittee of the American Aca Practice Parameter: Stroke prevention in patients with nonvalvular atrial fibrillation Neurology, September 1, 1998; 51(3): 671 - 673. [Full Text] [PDF]
|
|
|
|
|
|
R. G. Hart, D. G. Sherman, J. D. Easton, and J. A. Cairns Prevention of stroke in patients with nonvalvular atrial fibrillation Neurology, September 1, 1998; 51(3): 674 - 681. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. J. Powers and J. Zivin Magnetic resonance imaging in acute stroke: Not ready for prime time Neurology, April 1, 1998; 50(4): 842 - 843. [Full Text] [PDF]
|
|
|
|
|
|
M. Nuwer Assessment of digital EEG, quantitative EEG, and EEG brain mapping: Report of the American Academy of Neurology and the American Clinical Neurophysiology Society Neurology, July 1, 1997; 49(1): 277 - 292. [Full Text] [PDF]
|
|
|
|
|
|
E. Jodar, M. Munoz-Torres, F. Escobar-Jimenez, M. Quesada, J. D. Luna, and N. Olea Antiresorptive Therapy in Hyperthyroid Patients: Longitudinal Changes in Bone and Mineral Metabolism J. Clin. Endocrinol. Metab., June 1, 1997; 82(6): 1989 - 1994. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. M. LANE, E. H. RILEY, and P. Z. WIRGANOWICZ Instructional Course Lectures, The American Academy of Orthopaedic Surgeons - Osteoporosis: Diagnosis and Treatment*{{dagger}} J. Bone Joint Surg. Am., April 1, 1996; 78(4): 618 - 32. [Full Text]
|
|
Article
